

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)								
1. Name and Address Versant Venture	erson <sup>*</sup>	2. Date of Event Requiring Statement (Month/Day/Year) 11/18/2014		3. Issuer Name and Ticker or Trading Symbol SECOND SIGHT MEDICAL PRODUCTS INC [EYES]				
(Last) (First) (Middle) ONE SANSOME STREET, SUITE 3630			11/18/2014		4. Relationship of Reporting Person(s) to Issuer			5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)				(Check Director Officer (give ti below)		tleOther (specify below)		6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person
SAN FRANCISCO, CA 94104							X_Form filed by More than One Reporting Person	
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Beneficially Owned					
1.Title of Security (Instr. 4)				2. Amount of Se Beneficially Ow (Instr. 4)	ned	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Natur (Instr. 5	e of Indirect Beneficial Ownership )
Common Stock				4,370,964		Ι	see footnote (1)	
Common Stock				82,949		Ι	see footnote <sup>(2)</sup>	
Common Stock				38,062		Ι	see footnote (3)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1473 (7-02)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exercisable		3. Title and Amount of		4. Conversion	5. Ownership	6. Nature of Indirect Beneficial
(Instr. 4)	and Expiration Date		Securities Underlying Derivative		or Exercise	Form of	Ownership
	(Month/Day/Year)		Security		Price of	Derivative	(Instr. 5)
			(Instr. 4)		Derivative	Security: Direct	
		Expiration		Amount or Number of	Security	(D) or Indirect	
	Exercisable	Date	Title	Shares		(Instr. 5)	

# **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Versant Ventures II LLC ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA 94104		Х				
Versant Venture Capital II, LP ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA 94104		Х				
Versant Side Fund II, LP ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA 94104		Х				
Versant Affiliates Fund II-A, LP ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA 94104		Х				
ATWOOD BRIAN G ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA 94104		Х				

LINK WILLIAM J PHD ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA 94104	Х	Х	
MILDER DONALD B ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA 94104		х	
COLELLA SAMUEL D ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA 94104		Х	
JAFFE ROSS A MD ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA 94104		Х	

## Signatures

/s/ Robin L. Praeger	11/18/2014		
**Signature of Reporting Person	Date		

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares are held by Versant Venture Capital II, L.P. ("VVC II"). Versant Ventures II, LLC ("VV II") serves as the sole general partner of VVC II. Brian G. Atwood,
Samuel D. Colella, Ross A. Jaffe, William J. Link, Ph.D., Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Charles M. Warden, and Barbara N. Lubash are directors and/or members of VV II and share voting and dispositive power over the shares held by VVC II, however, each disclaim beneficial ownership of these shares, except to the extent of their pecuniary interest in such shares. William J. Link, Ph.D. is a director of the Issuer and, accordingly, files separate Section 16 reports.

The shares are held by Versant Affiliates Fund II-A, L.P. ("VAF II"). VV II serves as the sole general partner of VAF II. Brian G. Atwood, Samuel D. Colella, Ross A. (2) Jaffe, William J. Link, Ph.D., Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Charles M. Warden, and Barbara N. Lubash are directors and/or members of VV H and above units are directors and/or members of VV

(2) Justic, William J. Elin, Thild, J. Donard D. William J. Link, Ph.D. is a director of the Issuer and, accordingly, files separate Section 16 reports.
(2) The previous section of the secti

The shares are held by Versant Side Fund II, L.P. ("VSF II"). VV II serves as the sole general partner of VSF II. Brian G. Atwood, Samuel D. Colella, Ross A. Jaffe, William J. Link, Ph.D., Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Charles M. Warden, and Barbara N. Lubash are directors and/or members of VV II and charavertices and dimension and dimension and the second seco

(3) within J. Link, Ph.D., Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Charles M. Warden, and Barbara N. Lubash are directors and/or members of VV if and share voting and dispositive power over the shares held by VSF II, however, each disclaim beneficial ownership of these shares, except to the extent of their pecuniary interest in such shares. William J. Link, Ph.D. is a director of the Issuer and, accordingly, files separate Section 16 reports.

#### **Remarks:**

2 of 2

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.